Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated with High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation

Conclusion Even in an era of novel therapies, cytogenetically identified high-risk myeloma patients have worse prognoses than standard-risk myeloma patients after auto-HCT, and having > one high-risk cytogenetic abnormality further reduces survival. Teaser We retrospectively compared the outcomes of autologous hematopoietic stem cell transplantation (auto-HCT) among 670 multiple myeloma (MM) patients stratified as high-risk and standard-risk based on cytogenetic and FISH abnormalities. High-risk MM patients have shorter survival than standard-risk MM patients. Having > one high-risk cytogenetic abnormality and not achieving VGPR after auto-HCT further reduces survival.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research